Pangaea OncologyXMAD:PANG 63 Forward Dividend Yield % is 0.00% as of Jul. 01, 2026. GuruFocus rates XMAD:PANG with a GF Score™ of 63/100 and a GF Value™ of €2.15 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 61 Medical Diagnostics & Research companies, Pangaea Oncology ranks worse than 1639342.62% on this metric.
As of today (2026-07-01), the Forward Annual Dividend Yield of Pangaea Oncology is 0.00%.
As of today (2026-07-01), the Trailing Annual Dividend Yield of Pangaea Oncology is 0.00%.
XMAD:PANG's Forward Dividend Yield % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 1.86 * Ranked among companies with meaningful Forward Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Pangaea Oncology Forward Dividend Yield % Related Terms
XMAD:PANG vs TMO, DHR, IDXX: Forward Dividend Yield % Comparison
For the Diagnostics & Research subindustry, Pangaea Oncology's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pangaea Oncology Forward Dividend Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Pangaea Oncology's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Pangaea Oncology's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Pangaea Oncology (XMAD:PANG) has a Forward Dividend Yield % of 0.00% as of Jul. 01, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Pangaea Oncology and its competitors. According to the industry distribution chart, Pangaea Oncology ranks #999999 out of 61 companies in the Medical Diagnostics & Research industry.
Is Pangaea Oncology's Forward Dividend Yield % too high?
Pangaea Oncology's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Pangaea Oncology ranks #999999 out of 61 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Pangaea Oncology has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Pangaea Oncology's Forward Dividend Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Pangaea Oncology ranks #999999 out of 61 companies for Forward Dividend Yield %. This places Pangaea Oncology in the lower half of its industry. The industry median Forward Dividend Yield % is 1.86. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Medical Diagnostics & Research company?
The median Forward Dividend Yield % among Medical Diagnostics & Research companies is 1.86, based on 61 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Pangaea Oncology and its competitors. For the Medical Diagnostics & Research industry, the median Forward Dividend Yield % is 1.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pangaea Oncology's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pangaea Oncology stock overvalued right now?
Based on GuruFocus' analysis, Pangaea Oncology (XMAD:PANG) is currently considered Possible Value Trap. The stock's GF Value™ is €2.15, compared to a current price of €1.51 — trading 29.8% below its estimated fair value. The current Forward Dividend Yield % is 0.00%. Pangaea Oncology's overall GF Score™ is 63/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Pangaea Oncology (XMAD:PANG), the current Forward Dividend Yield % is 0.00% as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pangaea Oncology (XMAD:PANG) Overvalued in 2026?
Based on GuruFocus' analysis, Pangaea Oncology stock appears to be undervalued.
The current stock price of €1.51 is trading 29.8% below its estimated GF Value™ of €2.15.
GuruFocus considers Pangaea Oncology to be Possible Value Trap.
Key valuation signals for XMAD:PANG:
Forward Dividend Yield %: 0.00%
GF Value™: €2.15 vs. price of €1.51 (29.8% below fair value)
No single metric tells the full story. See the XMAD:PANG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pangaea Oncology SA is a medical services company. The company provides a wide range of services to cancer patients, as well as global pharmaceutical and biotech clients, in the fields of molecular diagnostics, clinical trials, in vitro drug profiling, dx platform validation, and biomarker discovery. The company has aggregated its operations into two segments, Clinical Care division and Diagnostic and Research and Development services division. Clinical Care division delivers medical oncology services and related activities. Diagnostic and Research and Development services division provides diagnostic and in-vitro services.
63GF Score
Get the complete analysis for XMAD:PANG
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:PANG has been successfully added to your 